Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3901
Genesco
GCO
$391M
| $413K | ﹤0.01% |
16,668
+2,668
| +19% | +$76.5K |
|
3902
Target Hospitality
TH
$1.61B
| $413K | ﹤0.01% |
51,503
+6,187
| +14% | +$47K |
|
3903
Forrester Research
FORR
$220M
| $412K | ﹤0.01% |
50,771
+1,712
| +3% | +$13.4K |
|
3904
iShares ESG Aware MSCI USA ETF
ESGU
$18.4B
| $411K | ﹤0.01% |
2,762
| – | – |
|
3905
abrdn Physical Gold Shares ETF
SGOL
$7.53B
| $411K | ﹤0.01% |
10,000
+1,208
| +14% | +$47.8K |
|
|
KEEL
3906
Keel Infrastructure Corp
KEEL
$2.19B
| $411K | ﹤0.01% |
174,733
+173,968
| +22,741% | +$595K |
|
|
ASIC
3907
Ategrity Specialty Insurance
ASIC
$1.18B
| $410K | ﹤0.01% |
19,526
+10,649
| +120% | +$201K |
|
3908
Anterix
ATEX
$1.74B
| $410K | ﹤0.01% |
18,789
+2,388
| +15% | +$49.6K |
|
3909
Paysafe
PSFE
$352M
| $408K | ﹤0.01% |
50,476
-83,238
| -62% | -$807K |
|
|
LAC
3910
Lithium Americas
LAC
$1.18B
| $408K | ﹤0.01% |
93,575
-18,614
| -17% | -$107K |
|
3911
CAE Inc. Common Shares
CAE
$8.9B
| $407K | ﹤0.01% |
13,385
-210,761
| -94% | -$5.91M |
|
|
BRT
3912
BRT Apartments
BRT
$268M
| $406K | ﹤0.01% |
27,630
+158
| +0.6% | +$2.33K |
|
3913
Kaltura
KLTR
$241M
| $402K | ﹤0.01% |
245,294
+13,034
| +6% | +$20.6K |
|
3914
CALL
DuPont de Nemours
DD
$19.5B
| $402K | ﹤0.01% |
3,333
-572,657
| -99% | -$64.4M |
|
3915
AdvisorShares Pure US Cannabis ETF
MSOS
$916M
| $401K | ﹤0.01% |
85,005
+60,005
| +240% | +$267K |
|
3916
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
$67.6B
| $401K | ﹤0.01% |
4,789
+4,751
| +12,503% | +$399K |
|
3917
John Marshall Bancorp
JMSB
$328M
| $401K | ﹤0.01% |
20,037
-1,310
| -6% | -$25.8K |
|
3918
Stratasys
SSYS
$767M
| $400K | ﹤0.01% |
46,039
+16,407
| +55% | +$163K |
|
3919
Codexis
CDXS
$175M
| $399K | ﹤0.01% |
244,851
+20,359
| +9% | +$41.5K |
|
3920
Vuzix
VUZI
$218M
| $398K | ﹤0.01% |
105,355
+13,872
| +15% | +$43.6K |
|
3921
VanEck Junior Gold Miners ETF
GDXJ
$8.59B
| $398K | ﹤0.01% |
3,495
-4,558
| -57% | -$471K |
|
3922
CALL
Helen of Troy
HELE
$696M
| $397K | ﹤0.01% |
18,700
| – | – |
|
3923
Designer Brands
DBI
$311M
| $397K | ﹤0.01% |
53,446
+7,237
| +16% | +$34.8K |
|
3924
Geospace Technologies
GEOS
$67.9M
| $395K | ﹤0.01% |
23,344
+17,583
| +305% | +$353K |
|
3925
iShares US Financials ETF
IYF
$4.41B
| $395K | ﹤0.01% |
+3,060
| New | +$383K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.